Pieter Evenepoel

List of Publications by Year in descending order

292 papers	16,185 citations	11651 70 h-index	20961 115 g-index
297 all docs	297 docs citations	297 times ranked	12200 citing authors

#	Article	IF	Citations
1	Prevalence, progression and implications of breast artery calcification in patients with chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 295-302.	2.9	6
2	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. American Journal of Kidney Diseases, 2022, 79, 667-676.e1.	1.9	25
3	Natural History of Bone Disease following Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 638-652.	6.1	12
4	Contemporary kidney transplantation has a limited impact on bone microarchitecture. Bone Reports, 2022, 16, 101172.	0.4	2
5	Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence. Toxins, 2022, 14, 210.	3.4	5
6	Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3532-e3533.	3.6	3
7	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients, 2022, 14, 1742.	4.1	8
8	MO587: Chronic Kidney Disease Induces Endotoxin-Related Activation of The Innate Immune System. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
9	Bone histomorphometry for the diagnosis of renal osteodystrophy: a call for harmonization of reference ranges. Kidney International, 2022, 102, 431-434.	5.2	5
10	Clinical utility of bone turnover markers in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 332-338.	2.0	6
11	Lipid Profile Is Negatively Associated with Uremic Toxins in Patients with Kidney Failureâ€"A Tri-National Cohort. Toxins, 2022, 14, 412.	3.4	5
12	Bone health in ageing men. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 1173-1208.	5.7	8
13	Vascular calcification of the abdominal aorta has minimal impact on lumbar spine bone density in patients with chronic kidney disease. Bone, 2022, 162, 116482.	2.9	8
14	Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 413-425.	0.7	30
15	European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4â€"G5D. Nephrology Dialysis Transplantation, 2021, 36, 42-59.	0.7	107
16	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrology Dialysis Transplantation, 2021, 36, 160-169.	0.7	19
17	Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. Journal of Endocrinological Investigation, 2021, 44, 1437-1446.	3.3	14
18	Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nature Reviews Nephrology, 2021, 17, 153-171.	9.6	126

#	Article	IF	Citations
19	Vitamin K in CKD Bone Disorders. Calcified Tissue International, 2021, 108, 476-485.	3.1	15
20	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. PLoS ONE, 2021, 16, e0247623.	2.5	14
21	Traditional and Non-traditional Risk Factors for Osteoporosis in CKD. Calcified Tissue International, 2021, 108, 496-511.	3.1	20
22	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	2.7	47
23	FC 076DIAGNOSTIC ACCURACY OF BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
24	MO455LIPID PROFILE AND UREMIC RETENTION SOLUTES IN PATIENTS WITH END-STAGE KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
25	Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. Kidney International, 2021, 99, 1173-1178.	5.2	11
26	FC 124PATTERNS OF RENAL OSTEODYSTROPHY ONE YEAR AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
27	MO568STATIC PARAMETERS OF HISTOMORPHOMETRY FOR THE EVALUATION OF BONE TURNOVER IN RENAL OSTEODYSTROPHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
28	MO524CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
29	MO792CONTEMPORARY MINERAL AND BONE DISORDER MARKERS AND TREATMENT AMONG HEMODIALYSIS PATIENTS IN THE EUROPEAN DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
30	European hemodialysis patient satisfaction with phosphate binders is associated with serum phosphorus levels: the Dialysis Outcomes and Practice Patterns Study (DOPPS). CKJ: Clinical Kidney Journal, 2021, 14, 1886-1893.	2.9	1
31	Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporosis International, 2021, 32, 2397-2405.	3.1	18
32	Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 855-865.	7.3	18
33	Patterns of renal osteodystrophy 1â€‰year after kidney transplantation. Nephrology Dialysis Transplantation, 2021, 36, 2130-2139.	0.7	11
34	Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study. , 2021, 31, 512-522.		29
35	Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney International, 2021, 100, 546-558.	5.2	39
36	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. Bone, 2021, 152, 116066.	2.9	7

#	Article	IF	Citations
37	Hepatic and Vascular Vitamin K Status in Patients with High Cardiovascular Risk. Nutrients, 2021, 13, 3490.	4.1	6
38	AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis. New England Journal of Medicine, 2021, 385, 1570-1580.	27.0	34
39	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. CKJ: Clinical Kidney Journal, 2021, 14, 1901-1907.	2.9	10
40	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrology Dialysis Transplantation, 2020, 35, 697-705.	0.7	21
41	Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients. CKJ: Clinical Kidney Journal, 2020, 13, 906-908.	2.9	1
42	Bone biomarkers in de novo renal transplant recipients. Clinica Chimica Acta, 2020, 501, 179-185.	1.1	9
43	Uremic Toxins and Vascular Calcificationâ€“Missing the Forest for All the Trees. Toxins, 2020, 12, 624.	3.4	14
44	Clinical evidence of direct bone effects of cinacalcet. Kidney International, 2020, 98, 514-515.	5.2	4
45	Therapy-Resistant Hypercalcemia in a Patient with Inactivating CYP24A1 Mutation and Recurrent Nephrolithiasis: Beware of Concomitant Hyperparathyroidism. Calcified Tissue International, 2020, 107, 524-528.	3.1	6
46	P1064HEPARIN-FREE DIALYSIS: A PHASE II PILOT STUDY USING ASYMMETRIC TRIACETATE (ATA) CELLULOSE DIALYZERS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
47	P1388ASSESSING BONE TURNOVER IN CHRONIC KIDNEY DISEASE: SHOULD WE MEASURE NON-OXIDIZED PTH. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
48	Spot urine versus 24-hour urine collection for estimation of the generation of uremic toxins originating from gut microbial metabolism. Kidney International, 2020, 98, 782-784.	5.2	1
49	Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study. European Journal of Endocrinology, 2020, 183, 181-189.	3.7	6
50	Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. Bone, 2020, 138, 115460.	2.9	14
51	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drugâ€“Bug Interaction?. Toxins, 2020, 12, 351.	3.4	14
52	Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. Nephrology Dialysis Transplantation, 2020, 35, 1794-1801.	0.7	37
53	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney International Reports, 2020, 5, 627-631.	0.8	13
54	A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy. JBMR Plus, 2020, 4, e10353.	2.7	12

#	Article	IF	Citations
55	The Role of Gut Dysbiosis in the Boneâ€“Vascular Axis in Chronic Kidney Disease. Toxins, 2020, 12, 285.	3.4	23
56	Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Scientific Reports, 2020, 10, 6586.	3.3	53
57	PTH Receptors and Skeletal Resistance to PTH Action. , 2020, , 51-77.		2
58	Sclerostin in chronic kidney diseaseâ€“mineral bone disorder think first before you block it!. Nephrology Dialysis Transplantation, 2019, 34, 408-414.	0.7	46
59	Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney International Reports, 2019, 4, 987-994.	0.8	12
60	Reply to: Poor Vitamin K Status in Chronic Kidney Disease: An Indirect Indicator of Hip Fragility. Journal of Bone and Mineral Research, 2019, 34, 1544-1545.	2.8	0
61	A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney International, 2019, 95, 412-419.	5.2	23
62	Intestinal microbiome and fitness in kidney disease. Nature Reviews Nephrology, 2019, 15, 531-545.	9.6	140
63	The Bone after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 795-797.	4.5	10
64	Bone mineral density, bone turnover markers, andÂincident fractures in de novo kidney transplantÂrecipients. Kidney International, 2019, 95, 1461-1470.	5.2	61
65	Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance. Journal of the American Society of Nephrology: JASN, 2019, 30, 751-766.	6.1	122
66	Bone-Vascular Axis in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2019, 26, 472-483.	1.4	53
67	Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease. Journal of Clinical Medicine, 2019, 8, 2027.	2.4	15
68	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
69	Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. Journal of Bone and Mineral Research, 2019, 34, 262-269.	2.8	51
70	Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. Pharmacological Research, 2018, 133, 101-107.	7.1	38
71	Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. Nephrology Dialysis Transplantation, 2018, 33, 1404-1410.	0.7	22
72	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes and Endocrinology,the, 2018, 6, 319-331.	11.4	102

#	Article	IF	Citations
73	Sclerostin deficiency modifies the development of CKD-MBD in mice. Bone, 2018, 107, 115-123.	2.9	20
74	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Diseaseâ€“Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Annals of Internal Medicine, 2018, 168, 422.	3.9	228
75	SuO003INDOXYL SULFATE AND P-CRESYL SULFATE PROMOTE VASCULAR CALCIFICATION BY GLUCOSE MEDIATED ACTIVATION OF INFLAMMATION AND COAGULATION PATHWAYS. Nephrology Dialysis Transplantation, 2018, 33, i617-i617.	0.7	0
76	Facing cinacalcet-induced hypocalcemia: sit back andÂrelax?. Kidney International, 2018, 93, 1275-1277.	5.2	12
77	Intestinal Barrier Function in Chronic Kidney Disease. Toxins, 2018, 10, 298.	3.4	78
78	Variations of sclerostin with other bone biomarkers over a one-year period in hemodialysis patients. Clinica Chimica Acta, 2018, 486, 183-184.	1.1	1
79	Clinical case report: a rare cause of acute kidney failure â€“ tissue is the issue. Acta Clinica Belgica, 2017, 72, 201-204.	1.2	3
80	Sclerostinâ”€A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. Kidney International Reports, 2017, 2, 481-485.	0.8	6
81	1Î²,25-Dihydroxyvitamin D 3 : A new vitamin D metabolite in human serum. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173, 341-348.	2.5	18
82	Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiativeâ€”a position paper. Nephrology Dialysis Transplantation, 2017, 32, 1608-1613.	0.7	41
83	Biomarkers Predicting Bone Turnover in the Setting of CKD. Current Osteoporosis Reports, 2017, 15, 178-186.	3.6	34
84	A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study. Nephrology Dialysis Transplantation, 2017, 32, 707-714.	0.7	20
85	Executive summary of the 2017 KDIGO Chronic KidneyÂDiseaseâ€“Mineral and Bone Disorder (CKD-MBD) Guideline Update: whatâ€™s changed and why it matters. Kidney International, 2017, 92, 26-36.	5.2	698
86	Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD?. Kidney International, 2017, 91, 11-13.	5.2	4
87	Bone histomorphometry in de novo renal transplant recipients indicates a further decline inÂbone resorption 1 year posttransplantation. Kidney International, 2017, 91, 469-476.	5.2	40
88	Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4210-4217.	3.6	15
89	Update on the role of bone biopsy in the management of patients with CKDâ€“MBD. Journal of Nephrology, 2017, 30, 645-652.	2.0	31
90	p -cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxinÂsky. Kidney International, 2017, 92, 1323-1324.	5.2	22

#	Article	IF	Citations
91	The gutâ€“kidney axis. Pediatric Nephrology, 2017, 32, 2005-2014.	1.7	188
92	Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS ONE, 2017, 12, e0176411.	2.5	37
93	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0153893.	2.5	74
94	Oxidative Stress in Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-2.	4.0	30
95	A liquid chromatography â€“ tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. Analytica Chimica Acta, 2016, 936, 149-156.	5.4	40
96	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
97	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. Transplantation, 2016, 100, 2188-2193.	1.0	21
98	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. EBioMedicine, 2016, 4, 162-169.	6.1	44
99	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3479-3487.	6.1	144
100	Metabolism, Protein Binding, and Renal Clearance of Microbiotaâ€“Derived p-Cresol in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1136-1144.	4.5	57
101	Mineral metabolism disturbances in kidney donors: smoke, no fire (yet). Kidney International, 2016, 90, 734-736.	5.2	1
102	Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney International, 2016, 90, 1184-1190.	5.2	123
103	Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease. JAMA Internal Medicine, 2016, 176, 867.	5.1	7
104	The Case | Hypercalcemia in a child with chronic kidney disease. Kidney International, 2016, 90, 233-234.	5.2	2
105	Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?. Kidney International, 2016, 89, 21-23.	5.2	7
106	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrology Dialysis Transplantation, 2016, 31, 1211-1219.	0.7	52
107	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. Nephrology Dialysis Transplantation, 2016, 31, 1508-1514.	0.7	32
108	The influence of renal transplantation on retained microbialâ€“human co-metabolites. Nephrology Dialysis Transplantation, 2016, 31, 1721-1729.	0.7	35

#	Article	IF	Citations
109	Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporosis International, 2016, 27, 489-497.	3.1	33
110	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. American Journal of Kidney Diseases, 2016, 67, 483-498.	1.9	271
111	The Influence of CKD on Colonic Microbial Metabolism. Journal of the American Society of Nephrology: JASN, 2016, 27, 1389-1399.	6.1	106
112	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. Journal of the American Society of Nephrology: JASN, 2016, 27, 281-292.	6.1	65
113	From skeletal to cardiovascular disease in 12 stepsâ€"the evolution of sclerostin as a major player in CKD-MBD. Pediatric Nephrology, 2016, 31, 195-206.	1.7	51
114	Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. Discoveries, 2016, 4, e55.	2.3	13
115	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. American Journal of Transplantation, 2015, 15, 2900-2907.	4.7	43
116	Microscopic nephrocalcinosis in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2015, 30, 843-848.	0.7	17
117	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). CKJ: Clinical Kidney Journal, 2015, 8, 567-571.	2.9	12
118	The fate of triaged and rejected manuscripts. Nephrology Dialysis Transplantation, 2015, 30, 1947-1950.	0.7	9
119	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. Clinical Infectious Diseases, 2015, 60, 1505-1511.	5.8	38
120	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
121	Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney International, 2015, 88, 235-240.	5.2	118
122	The metabolomics grail: promising although not yet holy. Kidney International, 2015, 87, 864.	5.2	1
123	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
124	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
125	Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4669-4676.	3.6	53
126	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney International, 2015, 87, 210-216.	5.2	52

#	Article	IF	Citations
127	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1525-1533.	4.5	59
128	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrology Dialysis Transplantation, 2015, 30, 288-293.	0.7	111
129	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. PLoS ONE, 2015, 10, e0140820.	2.5	77
130	Heritability and Clinical Determinants of Serum Indoxyl Sulfate and p-Cresyl Sulfate, Candidate Biomarkers of the Human Microbiome Enterotype. PLoS ONE, 2014, 9, e79682.	2.5	28
131	The Clinical Features of Trombotic Microangiopathies Post Transplantation.. Transplantation, 2014, 98, 532.	1.0	0
132	Proteinuria, Histology and Kidney-Allograft Survival.. Transplantation, 2014, 98, 78-79.	1.0	0
133	Heparin-coated dialyzer membranes: is non-inferiority good enough?. Kidney International, 2014, 86, 1084-1086.	5.2	18
134	Serum Concentrations of p-Cresyl Sulfate and Indoxyl Sulfate, But Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function. Peritoneal Dialysis International, 2014, 34, 71-78.	2.3	34
135	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. Kidney International, 2014, 86, 1001-1006.	5.2	13
136	A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism. American Journal of Transplantation, 2014, 14, 2545-2555.	4.7	77
137	Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 577.	1.6	0
138	The Histology of Kidney Transplant Failure. Transplantation, 2014, 98, 427-435.	1.0	124
139	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney International, 2014, 85, 636-640.	5.2	106
140	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. Nephrology Dialysis Transplantation, 2014, 29, 1965-1972.	0.7	10
141	Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?. Seminars in Nephrology, 2014, 34, 151-163.	1.6	62
142	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. Kidney International, 2013, 83, 789-791.	5.2	21
143	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transplant International, 2013, 26, 973-981.	1.6	36
144	Albumin is the main plasma binding protein for indoxyl sulfate and pâ€cresyl sulfate. Biopharmaceutics and Drug Disposition, 2013, 34, 165-175.	1.9	104

#	Article	IF	Citations
145	The Colon: An Overlooked Site for Therapeutics in Dialysis Patients. Seminars in Dialysis, 2013, 26, 323-332.	1.3	71
146	Safety Issues Related to Fractionated Plasma Separation, Adsorption, and Dialysis. Artificial Organs, 2013, 37, 743-744.	1.9	0
147	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. American Journal of Transplantation, 2013, 13, 1910-1914.	4.7	19
148	Renal safety in patients treated with bisphosphonates for osteoporosis: A review. Journal of Bone and Mineral Research, 2013, 28, 2049-2059.	2.8	91
149	Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients. Seminars in Nephrology, 2013, 33, 191-203.	1.6	81
150	Sclerostin: Another Vascular Calcification Inhibitor?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3221-3228.	3.6	143
151	Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. Nephrology Dialysis Transplantation, 2013, 28, 3024-3030.	0.7	105
152	Intrarenal Resistive Index after Renal Transplantation. New England Journal of Medicine, 2013, 369, 1797-1806.	27.0	185
153	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. Acta Clinica Belgica, 2013, 68, 215-217.	1.2	2
154	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1508-1514.	4.5	93
155	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transplant International, 2013, 26, 813-821.	1.6	51
156	Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparinâ€Induced Thrombocytopenia: Doseâ€Finding Study and Safety Evaluation. Artificial Organs, 2013, 37, 482-487.	1.9	21
157	Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrology Dialysis Transplantation, 2012, 27, 2017-2022.	0.7	36
158	Calcium balance in chronic kidney disease: walking the tightrope. Kidney International, 2012, 81, 1057-1059.	5.2	8
159	Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial. British Journal of Nutrition, 2012, 108, 2229-2242.	2.3	106
160	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. American Journal of Nephrology, 2012, 35, 24-30.	3.1	13
161	Evidence in Favor of a Severely Impaired Net Intestinal Calcium Absorption in Patients with (Early-Stage) Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 434-441.	3.1	17
162	Uremia Suppresses Immune Signal-Induced CYP27B1 Expression in Human Monocytes. American Journal of Nephrology, 2012, 36, 497-508.	3.1	34

#	Article	IF	Citations
163	Daytime Rhythm and Treatment-Related Fluctuations of Serum Phosphorus Concentration in Dialysis Patients. American Journal of Nephrology, 2012, 35, 242-248.	3.1	16
164	Mineral and bone disease - CKD 1-5. Nephrology Dialysis Transplantation, 2012, 27, ii146-ii158.	0.7	0
165	Transplantation - clinical I. Nephrology Dialysis Transplantation, 2012, 27, ii304-ii316.	0.7	2
166	Cardiovascular complications in CKD 5D. Nephrology Dialysis Transplantation, 2012, 27, ii227-ii251.	0.7	0
167	Bone and mineral diseases - 1. Nephrology Dialysis Transplantation, 2012, 27, ii36-ii37.	0.7	0
168	RecipientsÊ¼ Smoking Habits and Death-Censored Renal Allograft Survival. Transplantation, 2012, 94, 24.	1.0	0
169	Phosphate binder therapyâ€"cracks in the tower of strength?. Nature Reviews Nephrology, 2012, 8, 615-616.	9.6	4
170	Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. Kidney International, 2012, 81, 227-229.	5.2	41
171	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating Systemâ€Based Liver Dialysis. Artificial Organs, 2012, 36, 29-41.	1.9	9
172	Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient. Transplant International, 2012, 25, e27-e28.	1.6	3
173	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clinical Transplantation, 2012, 26, 393-402.	1.6	36
174	Prevalence and determinants of anemia in the immediate postkidney transplant period. Transplant International, 2011, 24, 1208-1215.	1.6	19
175	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. American Journal of Nephrology, 2011, 34, 226-232.	3.1	22
176	The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrology Dialysis Transplantation, 2011, 26, 759-761.	0.7	203
177	Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrology Dialysis Transplantation, 2011, 26, 1464-1467.	0.7	86
178	Calcium metabolism in the early post-transplant period. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2011, 63, 89-99.	3.9	1
179	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. Transplantation, 2010, 89, 341-346.	1.0	11
180	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. Transplantation, 2010, 89, 1296-1297.	1.0	6

#	Article	IF	Citations
181	Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1887-1892.	4.5	36
182	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1268-1276.	4.5	96
183	p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrology Dialysis Transplantation, 2010, 25, 219-224.	0.7	260
184	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrology Dialysis Transplantation, 2010, 25, 2672-2679.	0.7	77
185	Targeting hyperphosphatemia: truth or dare. Kidney International, 2010, 77, 256-257.	5.2	1
186	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2085-2092.	4.5	23
187	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1182-1189.	4.5	265
188	Quantification of 15N-Nitrate in Urine with Gas Chromatography Combustion Isotope Ratio Mass Spectrometry to Estimate Endogenous NO Production. Analytical Chemistry, 2010, 82, 601-607.	6.5	10
189	Coagulation and Fractionated Plasma Separation and Adsorption. American Journal of Transplantation, 2009, 9, 242-243.	4.7	3
190	p-Cresyl Sulfate and Indoxyl Sulfate in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1932-1938.	4.5	142
191	Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. Nephrology Dialysis Transplantation, 2009, 24, 3886-3890.	0.7	6
192	Uremic toxins originating from colonic microbial metabolism. Kidney International, 2009, 76, S12-S19.	5.2	349
193	Simultaneous Control of PTH and CaÃ—P Is Sustained over Three Years of Treatment with Cinacalcet HCl. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1465-1476.	4.5	29
194	Calcium Metabolism in the Early Posttransplantation Period. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 665-672.	4.5	72
195	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. American Journal of Transplantation, 2009, 9, 2470-2478.	4.7	46
196	Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial. American Journal of Kidney Diseases, 2009, 54, 77-85.	1.9	63
197	The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage. American Journal of Kidney Diseases, 2009, 54, 891-901.	1.9	219
198	Opinion: When is Vitamin D Contraindicated in Dialysis Patients?. Seminars in Dialysis, 2009, 22, 242-244.	1.3	0

#	Article	IF	Citations
199	Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. Journal of Chromatography A, 2009, 1216, 4684-4688.	3.7	65
200	Removal of the Uremic Retention Solute pâ€Cresol Using Fractionated Plasma Separation and Adsorption. Artificial Organs, 2008, 32, 214-219.	1.9	60
201	A Review of Albumin Binding in CKD. American Journal of Kidney Diseases, 2008, 51, 839-850.	1.9	99
202	Influenza Vaccination Is Efficacious and Safe in Renal Transplant Recipients. American Journal of Transplantation, 2008, 8, 332-337.	4.7	139
203	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. Nephron Clinical Practice, 2008, 110, c80-c85.	2.3	51
204	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. Journal of Antimicrobial Chemotherapy, 2008, 63, 417-419.	3.0	29
205	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrology Dialysis Transplantation, 2008, 23, 2033-2042.	0.7	65
206	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney International, 2008, 74, 265-275.	5.2	40
207	Recovery of Hyperphosphatoninism and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1829-1836.	4.5	124
208	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2008, 24, 278-285.	0.7	70
209	Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International, 2008, 73, 1174-1180.	5.2	276
210	Living donor kidney transplantation: analysis of the first 40 cases performed in UZ Leuven. Acta Chirurgica Belgica, 2008, 108, 39-44.	0.4	0
211	Control of hyperphosphatemia beyond phosphate. Kidney International, 2007, 71, 376-379.	5.2	12
212	Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrology Dialysis Transplantation, 2007, 22, 1730-1737.	0.7	96
213	Response to â€˜Superior dialytic clearance of Î²2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysisâ€™. Kidney International, 2007, 71, 467-468.	5.2	1
214	Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. Transplant International, 2007, 20, 381-385.	1.6	24
215	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. British Journal of Dermatology, 2007, 158, 071018053044006-???.	1.5	29
216	Tertiary â€˜Hyperphosphatoninismâ€™ Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 1193-1200.	4.7	143

#	Article	IF	Citations
217	Major Coagulation Disturbances During Fractionated Plasma Separation and Adsorption. American Journal of Transplantation, 2007, 7, 2195-2199.	4.7	65
218	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. American Journal of Kidney Diseases, 2007, 49, 642-649.	1.9	68
219	Late Referral of Patients With Chronic Kidney Disease: No Time to Waste. Mayo Clinic Proceedings, 2006, 81, 1487-1494.	3.0	50
220	The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon. British Journal of Nutrition, 2006, 96, 1078-1086.	2.3	53
221	Effect of MARS and PROMETHEUS on systemic hemodynamics and vasoactive agents in patients with acute on-chronic alcoholic liver failure: the clash of the titans. European Journal of Gastroenterology and Hepatology, 2006, 18, A38.	1.6	2
222	Clinically Relevant Drug Interaction Between Voriconazole and Tacrolimus in a Primary Renal Allograft Recipient. Transplantation, 2006, 81, 1750-1752.	1.0	21
223	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. Artificial Organs, 2006, 30, 276-284.	1.9	105
224	Review article: nonâ€biological liver support in liver failure. Alimentary Pharmacology and Therapeutics, 2006, 23, 351-363.	3.7	59
225	Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney International, 2006, 69, 1081-1087.	5.2	340
226	Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study. Kidney International, 2006, 70, 192-198.	5.2	63
227	Superior dialytic clearance of Î²2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney International, 2006, 70, 794-799.	5.2	93
228	Drug Interaction Between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient. Transplantation, 2005, 79, 737.	1.0	21
229	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney International, 2005, 67, 2477-2487.	5.2	108
230	In vivo evaluation of a colonic delivery system using isotope techniques. Alimentary Pharmacology and Therapeutics, 2005, 21, 187-194.	3.7	16
231	Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. American Journal of Kidney Diseases, 2005, 45, e33-e37.	1.9	30
232	Time Profiles of Peritoneal and Renal Clearances of Different Uremic Solutes in Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2005, 46, 512-519.	1.9	77
233	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 1997-2004.	4.7	157
234	The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transplantation, 2005, 11, 853-854.	2.4	10

#	Article	IF	Citations
235	Gas Chromatographicâ€“Mass Spectrometric Analysis for Measurement of p-Cresol and Its Conjugated Metabolites in Uremic and Normal Serum. Clinical Chemistry, 2005, 51, 1535-1538.	3.2	172
236	A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. Journal of Antimicrobial Chemotherapy, 2005, 55, 391-394.	3.0	8
237	Detoxifying Capacity and Kinetics of Prometheus^{Â®} â€“ A New Extracorporeal System for the Treatment of Liver Failure. Blood Purification, 2005, 23, 349-358.	1.8	82
238	A Prospective, Randomized, Double-Blind Crossover Study on the Use of 5% Citrate Lock versus 10% Citrate Lock in Permanent Hemodialysis Catheters. Blood Purification, 2005, 23, 101-105.	1.8	27
239	Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrology Dialysis Transplantation, 2005, 20, 1714-1720.	0.7	123
240	Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation. Transplantation Proceedings, 2005, 37, 2840-2842.	0.6	10
241	Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. American Journal of Clinical Nutrition, 2004, 80, 1536-1543.	4.7	62
242	Heparin-Coated Hemodialyzers â€“The Holy Grail for Patients at Risk of Bleeding?. Nephron Clinical Practice, 2004, 97, c1-c2.	2.3	1
243	Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrology Dialysis Transplantation, 2004, 19, 469-473.	0.7	69
244	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrology Dialysis Transplantation, 2004, 19, 1281-1287.	0.7	273
245	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrology Dialysis Transplantation, 2004, 19, 1895-1901.	0.7	83
246	The value of tuberculin skin testing in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 433-438.	0.7	54
247	Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney International, 2004, 65, 1842-1849.	5.2	206
248	Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. American Journal of Kidney Diseases, 2004, 44, 278-285.	1.9	155
249	Acute toxic renal failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2004, 18, 37-52.	4.0	52
250	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. Drug Metabolism and Disposition, 2004, 32, 1421-1425.	3.3	28
251	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics, 2004, 75, 434-447.	4.7	157
252	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. Clinical Pharmacokinetics, 2004, 43, 741-762.	3.5	102

#	Article	IF	Citations
253	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal of Medicine, 2004, 350, 1516-1525.	27.0	1,023
254	189 Improvement in systemic hemodynamics after mars is associated with a decrease in vasoactive substances in patients with acute on chronic liver failure (AOCLF): Results of a randomised trial. Journal of Hepatology, 2004, 40, 61-62.	3.7	1
255	Validation of a New Test Meal for a Protein Digestion Breath Test in Humans. Journal of Nutrition, 2004, 134, 806-810.	2.9	21
256	Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clinical Transplantation, 2003, 17, 171-176.	1.6	12
257	The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clinical Transplantation, 2003, 17, 234-241.	1.6	54
258	Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney International, 2003, 64, 2238-2243.	5.2	178
259	Evidence for impaired assimilation of protein in chronic renal failure. Kidney International, 2003, 64, 2196-2203.	5.2	107
260	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. Journal of Clinical Pharmacology, 2003, 43, 866-880.	2.0	99
261	A young patient with unexplained acute hepatorenal dysfunction. Nephrology Dialysis Transplantation, 2003, 18, 1220-1222.	0.7	4
262	13C-breath tests in peritoneal dialysis patients. European Journal of Gastroenterology and Hepatology, 2003, 15, 931-932.	1.6	3
263	Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients. Therapeutic Drug Monitoring, 2003, 25, 447-451.	2.0	20
264	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation, 2003, 75, 665-672.	1.0	142
265	C3D DEPOSITION IN PERITUBULAR CAPILLARIES INDICATES A VARIANT OF ACUTE RENAL ALLOGRAFT REJECTION CHARACTERIZED BY A WORSE CLINICAL OUTCOME. Transplantation, 2003, 76, 102-108.	1.0	47
266	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. Blood Purification, 2003, 21, 244-252.	1.8	44
267	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrology Dialysis Transplantation, 2002, 17, 923-926.	0.7	38
268	role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplantation Proceedings, 2002, 34, 1164-1170.	0.6	18
269	Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant Recipients. American Journal of Transplantation, 2002, 2, 989-992.	4.7	58
270	Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. American Journal of Kidney Diseases, 2002, 39, 315-323.	1.9	60

#	Article	IF	Citations
271	Magnesium chloride slows gastric emptying, but does not affect digestive functions. Alimentary Pharmacology and Therapeutics, 2002, 16, 1571-1577.	3.7	6
272	Gastric emptying in renal failure patients using the 13C-octanoic acid breath test: facts and artifacts. Peritoneal Dialysis International, 2002, 22, 732-3; author reply 734-5.	2.3	0
273	â€˜Full houseâ€™ positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrology Dialysis Transplantation, 2001, 16, 2258-2262.	0.7	25
274	Alteration in digestion and absorption of nutrients during profound acid suppression. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2001, 15, 539-551.	2.4	26
275	THE EFFECT OF MYCOPHENOLATE MOFETIL ON HEPATITIS B VIRAL LOAD IN STABLE RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS B. Transplantation, 2001, 72, 1165-1166.	1.0	15
276	Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655.. Transplantation, 2001, 72, 1593-1594.	1.0	4
277	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. Transplantation, 2001, 72, 1655-1661.	1.0	128
278	A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. International Journal of Artificial Organs, 2001, 24, 208-11.	1.4	17
279	Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. Acta Oto-rhino-laryngologica Belgica, 2001, 55, 177-86.	0.0	6
280	Death with functioning graft--a preventable cause of graft loss. Annals of Transplantation, 2001, 6, 17-20.	0.9	7
281	Dialysis Techniques in the Critic Ally-Ill Patient. Acta Clinica Belgica, 2000, 55, 237-243.	1.2	0
282	13C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine. Gut, 2000, 46, 52-57.	12.1	27
283	Amount and fate of egg protein escaping assimilation in the small intestine of humans. American Journal of Physiology - Renal Physiology, 1999, 277, G935-G943.	3.4	85
284	Gastric emptying in hyperemesis gravidarum and non-dyspeptic pregnancy. Alimentary Pharmacology and Therapeutics, 1999, 13, 237-243.	3.7	88
285	Determination of Deuterated Phenylalanine and Tyrosine in Egg Protein by GCQ. Journal of High Resolution Chromatography, 1999, 22, 465-468.	1.4	2
286	Validation of the lactose-[13C]ureide breath test for determination of orocecal transit time by scintigraphy. Journal of Nuclear Medicine, 1999, 40, 1451-5.	5.0	57
287	Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. Alimentary Pharmacology and Therapeutics, 1998, 12, 1011-1019.	3.7	74
288	Digestibility of Cooked and Raw Egg Protein in Humans as Assessed by Stable Isotope Techniques. Journal of Nutrition, 1998, 128, 1716-1722.	2.9	116

#	Article	IF	Citations
289	Study of protein assimilation, using stable isotope techniques. Revista De Medicina De La Universidad De Navarra, 1998, 42, 104-8.	0.0	1
290	Production of Egg Proteins, Enriched with L-Leucine-13C1, for the Study of Protein Assimilation in Humans Using the Breath Test Technique ,. Journal of Nutrition, 1997, 127, 327-331.	2.9	38
291	Influence of dietary protein supplements on the formation of bacterial metabolites in the colon.. Gut, 1997, 41, 70-76.	12.1	200
292	Evaluation of the role of gastric digestion in overall protein assimilation by a combined13C-egg white -14C-octanoic acid breath test. European Journal of Nutrition, 1997, 36, 374-374.	4.6	0